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ProtectionA coronavirus vector based on the genome of the porcine transmissible gastroenteritis virus (TGEV)
expressing the rotavirus VP7 protein was constructed to immunize and protect against rotavirus infections in
a murine model. The tropism of this TGEV-derived vector was modiﬁed by replacing the spike S protein with
the homologous protein frommouse hepatitis virus (MHV). The rotavirus gene encoding the VP7 protein was
cloned into the coronavirus cDNA. BALB/c and STAT1-deﬁcient mice were inoculated with the recombinant
viral vector rTGEVS-MHV–VP7, which replicates in the intestine and spreads to other organs such as liver,
spleen and lungs. TGEV-speciﬁc antibodies were detected in all the inoculated BALB/c mice, while rotavirus-
speciﬁc antibodies were found only after immunization by the intraperitoneal route. Partial protection against
rotavirus-induced diarrhea was achieved in suckling BALB/c mice born to dams immunized with the
recombinant virus expressing VP7 when they were orally challenged with the homotypic rotavirus strain.School of Medicine, University
ain. Fax: +34 96 386 4960.
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Transmissible gastroenteritis virus (TGEV) is a member of the
Coronaviridae family within the Nidovirales order (Enjuanes et al.,
2000). TGEV has a single-stranded, plus sense 28.5-kb RNA genome
(Penzes et al., 2001). Open reading frames (ORFs) 1a and 1b, which
encode the replicase (rep) are located at the 5′-end of the genome and
comprise approximately two-thirds of the entire RNA. The 3′-end of
the genome includes the genes encoding structural and nonstructural
proteins, in the order 5′-S-3a-3b-E-M-N-7-3′ and occupy one-third of
the genome (Enjuanes et al., 2000; de Groot et al., 2010). TGEVs are
enveloped spherical viruses containing four essential structural
proteins: the membrane (M), the small envelope (E), the spike (S),
and the nucleocapsid (N) proteins. The M protein spans the
membrane three or four times and interacts with the nucleocapsid
(N) and spike (S) proteins during assembly (Escors et al., 2001). The S
protein, a large type I transmembrane glycoprotein, forms peplomers
and is responsible for viral attachment to speciﬁc host receptors and
membrane fusion (Lewicki and Gallagher, 2002; Sune et al., 1990).
The small envelope (E) protein is a transmembrane protein that is
present as a minor structural component. The N protein wraps thegenomic RNA into a nucleocapsid (Escors et al., 2001; Kapke and
Brian, 1986).
Coronaviruses have several advantages as vectors over other viral
expression systems: (i) they are single-stranded RNA viruses that
replicate in the cytoplasm without a DNA intermediary, making
integration of the virus genome into the host cell chromosome
unlikely (Lai and Cavanagh, 1997); (ii) these viruses have the largest
RNA virus genome and, in principle, have room for the insertion of
large foreign genes (Enjuanes et al., 2001); (iii) a pleiotropic secretory
immune response is best induced by the stimulation of gut-associated
lymphoid tissues. Since coronaviruses generally infect mucosal
surfaces, both respiratory and enteric, they could be used to target
the antigen to the enteric and respiratory areas to induce a strong
secretory immune response; (iv) the tropism of coronaviruses may be
engineered by modifying the S gene (Haijema et al., 2003; Kuo et al.,
2000; Sanchez et al., 1999); (v) nonpathogenic coronavirus strains
infecting most species of interest (human, porcine, bovine, canine,
feline, and avian) are available and therefore suitable to develop safe
vectors; and (vi) infectious coronavirus cDNA clones (Almazan et al.,
2000; Casais et al., 2001; Thiel et al., 2001; Yount et al., 2003) and
coronavirus-derived replicons (Almazan et al., 2004, 2006) are
available to design expression systems.
Rotavirus is the main cause of diarrhea-related illness and death in
children worldwide. It is associated with 25 million outpatient visits,
more than 2.3 million hospitalizations and up to 600,000 deaths in
children b5 years old (Parashar et al., 2006). Rotavirus infection
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severe watery diarrhea, often leading to dehydration (Kapikian et al.,
2001). Children usually become infected in the ﬁrst 3–5 years of life,
with the highest incidence in those aged b2 years. Naturally acquired
rotavirus infection protects against subsequent severe disease,
particularly following repeated exposures (Velazquez et al., 1996).
Rotavirus is a member of the Reoviridae family. The virion is a
nonenveloped particle and possesses a triple layered capsid structure
that surrounds the genome composed of 11 segments of double-
stranded RNA. There are six structural proteins and six nonstructural
proteins, each protein being encoded by a unique genome segment
except for two nonstructural proteins (NSP5 and NSP6), which are
encoded by an overlapping reading frame of a single segment. The
antigenic properties of group, subgroup and serotype/genotype of
rotaviruses are determined by the viral capsid proteins (VP), named
VP6, VP4 and VP7. VP4 and VP7 (the outer capsid proteins) contain
epitopes that elicit neutralizing antibodies (Kapikian et al., 2001).
The use of recombinant viruses is a very promising approach in the
design of new vaccines against rotavirus. In this study, a viral vector
has been developed based on porcine transmissible gastroenteritis
coronavirus (TGEV) full-length genome sequence expressing the
rotavirus VP7 protein. Genetic engineering techniques were used to
generate this recombinant vector from a cDNA fragment containing
the full-length genome sequence of TGEV. Thereafter, the tropism of
the TGEV-derived vector was modiﬁed by replacing the spike
S protein with the homologous protein from mouse hepatitis virus
(MHV-A59 strain). The recombinant vector replicated stably in vitro in
murine cell cultures producing the rotavirus VP7 protein. The vector
was inoculated to BALB/c and STAT1−/−mice and in vivo replication
was conﬁrmed in different organs by RT-PCR and immunoﬂuores-+ Rep 1a Rep 1b
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Fig. 1. Rescue of rTGEVS-MHV/C11 from cDNA in LR7 cells. (A) Genetic organization of the rTGE
genome. Letters and numbers indicate the viral genes. TRS-SC11, transcription regulating seq
SC11, TGEV S gene. (B) Genetic organization of the rTGEVS-MHV/C11-VP7 virus. Restriction sicence of histological sections. BALB/c mice immunizedwith the vector
produced rotavirus-speciﬁc IgG and IgA class antibodies, as deter-
mined by enzyme-linked immunosorbent assay. Cytokine production
in serum samples and cultivated splenocytes of inoculated mice was
determined by analysing protein levels of 10 cytokines using a
multiplex bead-based ﬂow cytometry assay. The protection study in
the newborn mouse model demonstrated partial protection (62% of
the challenged animals) against rotavirus-induced diarrhea by the
homotypic rotavirus RF strain.
Results
Generation of rTGEVS-MHV/C11
Recombinant rTGEVS-MHV/C11 was obtained by using the strategy
described to generate a cDNA encoding a full-length TGEV RNA
(Almazan et al., 2000). The plasmid pBAC-TGEV-SMHV-C11 was
transfected into BHK-21 cells that 6 h later were overlaid into
monolayers of murine LR7 or porcine ST cells to select for recombinants
that had acquired the ability to infect murine cells and had simulta-
neously lost the ability to infect porcine cells (Fig. 1). LR7 monolayers
cocultured with BHK-21 transfected cells exhibited syncytia formation
48 h posttransfection. By contrast, ST monolayers cocultured with BHK-
21 transfected cells did not showdetectable cytopathic effect, even up to
96 h posttransfection (data not shown). The growth kinetics of the
rTGEVS-MHV/C11, TGEV, andMHV-A59 in porcine ST andmurine LR7 cells
were compared (Fig. 2). Thegrowth rate ofMHV-A59and rTGEVS-MHV/C11
was quite similar; however, MHV-A59 reached a peak titer
(3×106 PFU/mL) sooner than rTGEVS-MHV/C11 (5×105 PFU/mL), at
12 and 24 h postinfection, respectively. As expected, TGEV replicated3a 7 UTR3b M NE AAA
Mlu I Pme I
Asc IFse I
Swa I
Fse I
HV-A59 TM SC11
-A59/C11
Mlu I  
1
ST
7 UTRORF9VP7
M NE AAA
Mlu I Pme I
Asc I
Blp I
Fse I
-A59/C11
VS-MHV/C11 virus. Restriction sites Pac I, Mlu I, Fse I, Pme I, and Asc I are indicated in the
uence of TGEV-C11 S gene; SMHV-A59, MHV-A59 S gene; TM, transmembrane domain;
tes Pac I, Mlu I, Blp I, FseI, Pme I, and Asc I are indicated in the genome.
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Fig. 2. Growth kinetics of rTGEVS-MHV/C11 inmurine and porcine cells. The viral infectivity
of rTGEVS-MHV/C11, TGEV, and MHV-A59 in murine LR7 (A) and porcine ST cells (B) was
determined at different times postinfection by plaque assay. Mean values from four
experiments are represented, and standard deviations are shown as error bars.
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failed to grow, thus indicating that TGEV S protein replacement with
the chimerical TGEV-MHV-A59 S protein had altered the host species
speciﬁcity of the virus (Fig. 2).
Tissue culture growth phenotype of rTGEVS-MHV/C11
To analyze the growth characteristics of the recombinant viruses,
murine LR7 and porcine ST cells were infected with rTGEVS-MHV/C11, as
well as with the parental viruses TGEV and MHV-A59. Consistently,
recombinant viruses were unable to produce syncytia or cytopathic
effects in porcine ST cells. As shown in Fig. 3A, no plaques of any size
were evident on ST cell monolayers at 72 h postinoculation with
recombinant viruses, in contrast to the plaques generated by wild-type
TGEV on the same cells. In the same postinfection period, however,
smaller plaqueswere obvious on LR7 cells infectedwith rTGEVS-MHV/C11,
while wild-type TGEV was unable to form plaques on these cells. These
results conﬁrmed that TGEV S protein replacement with chimerical
TGEV/MHV S proteinwas sufﬁcient to change the species tropismof the
virus. The rTGEVS-MHV/C11 virus grew successfully in LR7 cells, causing an
extensive syncytia and cytopathic effect comparable to that of MHV-
A59. This indicated that rTGEVS-MHV/C11 had acquired the capacity to
generate syncytia, which is typical of MHV-A59 but not of TGEV, due to
the expression of the MHV-A59 S protein (Fig. 3B). These results were
further conﬁrmed by infecting CMR cells (Caco-2 transfected with the
MHV receptor) with rTGEVS-MHV/C11 (results not shown). The growth
kinetics of the recombinant rTGEVS-MHV/C11 vector in different murine
cells lines showed that LR7was themost productive cell line, reaching atiter of 6×107 FFU/mL). The CMR cells yielded titers of 106 FFU/mL,
whereas other cell lines (3T3, MC57 and BALB Cl.7) yielded lower titers
(less than 104 FFU/mL) (results not shown).
Analysis of the rTGEVS-MHV/C11 proteins
To verify the identity of rTGEVS-MHV/C11, we characterized the
recombinant virus at the protein level, particularly its S protein. Murine
LR7 and porcine ST cells were infectedwith rTGEVS-MHV/C11. As controls,
both cell lines were infected with TGEV and MHV-A59 and analyzed in
parallel. The infected cells were incubated with MAbs speciﬁc for the
MHV-A59 S protein (α-S-MHV) and TGEV M (α-M-TGEV) protein. In
TGEV-infected ST cells, a speciﬁc immunoﬂuorescence signal was only
observed when probed with α-M-TGEV antibodies but not with
α-S-MHV. The MHV-infected LR7 cells emitted a speciﬁc signal only
when treated with α-S-MHV antibodies but not with α-M-TGEV
(Fig. 3B). The analysis of the rTGEVS-MHV/C11-infected LR7 cells revealed
a speciﬁc immunoﬂuorescence signal after treatment with antibodies
α-M-TGEV and α-S-MHV, demonstrating that rTGEVS-MHV/C11
expressed TGEV proteins, but also the MHV-A59 S protein.
Generation of recombinant rTGEVS-MHV/C11 vector expressing rotavirus
VP7
To recover infectious rTGEVS-MHV/C11-VP7 from pBAC-TGEV-SMHV-
C11-VP7 plasmid, BHK-21 cells were grown to 95% conﬂuence and
transfected with the cDNA clones. At 6 h posttransfection, cells were
trypsinized, plated over a conﬂuent monolayer of LR7, and incubated at
37 °C for 72 h. After two passages in LR7, the recovered viruswas cloned
by three rounds of plaque puriﬁcation. The expression of heterologous
VP7 protein in murine cells was veriﬁed by indirect immunoﬂuores-
cence on rTGEVS-MHV/C11-VP7-infected LR7 cells (Fig. 4). In contrast to
cells that were infected with rTGEVS-MHV/C11, a strong ﬂuorescence was
shown by rTGEVS-MHV/C11-VP7-infected cells, indicating the successful
expression of the VP7 protein. VP7 was detected primarily in the
cytoplasm.We also performed confocal ﬂuorescentmicroscopy on cells
infected with rTGEVS-MHV/C11-VP7 and found that the VP7 protein was
distributed evenly throughout the cytoplasm but not in the nucleus. To
study the expression kinetics of VP7 protein following rTGEVS-MHV/C11-
VP7 infection, LR7 cells were infected and aliquots were taken at
different times. The virus growth kinetics showed that the maximum
virus titer was reached at 20 h.p.i., whereas maximum protein
expression was at 22 h.p.i. (data not shown).
To check the stability of the recombinant virus several rounds of
puriﬁcation were performed by limited dilution in 96-well plates to
isolate a clone of rTGEVS-MHV/C11-VP7 that expresses the heterologous
protein. The isolated clones were tested to conﬁrm the presence of the
ORF9 gene in the viral genome through RNA isolation and RT-PCR. The
expression of the heterologous VP7 protein was conﬁrmed by
immunoﬂuorescence. After ﬁve puriﬁcation steps, virus clone 12A
was obtained.When this clone was ampliﬁed, VP7was expressed in at
least 20% of the infected cells, and the expression was stable.
‘In vivo’ replication of rTGEVS-MHV/C11
The ability of rTGEVS-MHV/C11-VP7 virus to infect mice was assayed.
Eight BALB/c and 12 STAT1−/− mice were inoculated with 2×106
FFU/mice by the oro-nasal route. On speciﬁed days, the mice were
sacriﬁced and spleen, liver, intestine, lungs and sera were extracted.
Subgenomic viral RNA was detected with RNA extraction and RT-PCR
of the N viral gene. The results revealed the presence of viral RNA in
different organs of BALB/cmice (intestine, liver, spleen and lungs) and
in STAT1-deﬁcient mice in the small and large intestine for a 6-day
period. These results were conﬁrmed by the isolation of infectious
virus in cell culture. To verify virus active replication, two STAT1-
deﬁcient mice were inoculated. The mice were sacriﬁced at 48 and
Fig. 3. Growth phenotype of rTGEVS-MHV/C11 in LR7murine and ST porcine cells. (A)Monolayers of murine LR7 and porcine ST cells were infectedwith rTGEVS-MHV/C11, TGEV orMHV-A59.
Cytopathic effect was analyzed by plaque assay and opticalmicroscopy and visualized at 72 h postinfection. (B) Immunoﬂuorescence analysis of rTGEVS-MHV/C11-infected cells. LR7 and ST
cells were infected with rTGEVS-MHV/C11, TGEV or MHV-A59. Infections were visualized at 24 h.p.i. by immunoﬂuorescence microscopy on permeabilized cells with speciﬁc MAbs against
TGEV M protein (α-M-TGEV) and MHV-A59 S protein (α-S-MHV).
110 J.M. Ribes et al. / Virology 410 (2011) 107–11872 h and the intestine, spleen, liver and lungs were collected. Viral
antigens were found in the submucosa of the small intestine, in
spleen, liver and lungs, conﬁrming viral replication in these organs
(Table 1 and Fig. 5).
Antibody responses to rTGEVS-MHV/C11 and rTGEVS-MHV/C11-VP7 recombinant
viruses in immunized mice
TGEV and rotavirus-speciﬁc serum IgA and IgG antibody responses
were evaluated in BALB/c mice inoculated by intraperitoneal, intragas-
tric or intranasal routes with rTGEVS-MHV/C11-VP7. One control group
was inoculated intragastrically with rTGEVS-MHV/C11. Anti-TGEV serum
IgG antibody responses were detected at high titers in the mice
inoculated intranasally and intraperitoneally (1/2500) (pb0.05), and atlower titers in mice inoculated intragastrically (1/500) (pb0.05)
(Fig. 6A). We examined whether intranasal inoculation of rTGEV
produces antigen-speciﬁc IgA in the mucosal compartment. To test
whether a mucosal response was induced, intestinal contents as well as
serum samples from immunizedmicewere analyzed by ELISA for TGEV
intestinal IgA. The second inoculation of rTGEV led to a signiﬁcant
increase (pb0.05) of detectable serum IgA, which rose slightly after the
third inoculation (Fig. 7). IgA levels in the intestinal contents varied
between animals, with detection of IgA production in the intestinal
lumen in two out of six inoculated mice (results not shown). The
rTGEVS-MHV/C11-VP7 vector induced speciﬁc antibodies against rotavirus
in mice. A single dose of rTGEVS-MHV/C11-VP7 by the intraperitoneal
route induced rotavirus-speciﬁc antibodies in immunized mice
(pb0.05), with a further increase after the second immunization. The
Fig. 4. Expression of VP7 protein in LR7 cells infected with rTGEVS-MHV/C11-VP7 detected by immunoﬂuorescence assay. LR7 cells were infected with rTGEVS-MHV/C11-VP7 (MOI=1),
at 24 h.p.i. cells were ﬁxed in metanol/acetone for 10 min and stained with a sheep polyclonal anti-rotavirus antibody (Silenus) and 3D.C10 MAb to recognize N protein of TGEV. An
appropriate secondary ﬂuorescent-conjugated antibody was applied (Cy5-labeled anti-sheep IgG to detect rotavirus protein and FITC-labeled anti-mouse IgG to reveal TGEV
protein).
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the absence of an anti-VP7 response in the rTGEVS-MHV/C11-immunized
mice (Fig. 6B). No fecal IgA against rotavirus was detected in any group.
The neutralizing activity of these IgG antibodies was also assessed, and
neutralizing antibody levels increased in the rTGEVS-MHV/C11-VP7 mice
inoculated intraperitoneally compared to the preimmune mice, with
differences near the conﬁdence level of 5% (p=0.079).Table 1
TGEV RNA detection by RT-PCR in rTGEVS-MHV/C11-inoculated BALB/c and STAT1−/−
mice. Eight BALB/c and 12 STAT1−/− mice were oro-nasally inoculated with 2×106
FFU of rTGEVS-MHV/C11. Mice were euthanized on the days indicated, and their organs
were removed, weighed, and resuspended as 10% (w/v) tissue homogenate in PBS. RNA
from the resulting homogenates was extracted and RT-PCRwith speciﬁc primers for the
N viral gene was performed. GAPDH gene was also investigated by RT-PCR as an RNA
extraction control. Results corresponding to the organs obtained from BALB/c (A) and
STAT1−/− (B) mice are shown.
A) BALB/c mice
Spleen Liver Intestine Lung Serum Stools
Day 1 ++ − − + ++ +
Day 2 − ++ ++ + + +
Day 3 − + − − + −
Day 4 − + − − − −
B) STAT1−/− mice
Spleen Liver Small intestine Large intestine Serum Stools
Day 1 − − + + − +
Day 2 ++ ++ ++ + − +
Day 3 ++ ++ ++ + − −
Day 4 ++ − ++ + − −
Day 5 + − ++ + ND ND
Day 6 − − + + ND ND
+, positive result by RT-PCR for TGEV N gene.
++, very intense amplicon by RT-PCR for TGEV N gene.
ND, not determined.Cytokine analyses
Cytokine levels in the serum samples and splenocytes stimulated in
vitro were studied in 6 BALB/c mice inoculated three times at 2-week
intervals with rTGEVS-MHV/C11-VP7 and six mice with rTGEVS-MHV/C11.
GM-CSF levels were signiﬁcantly increased (41 pg/mL) in the sera from
mice 48 h postinoculation. Also, increased levels of IL-2 (30 pg/mL)
were present in the sera at 48 h postinoculation (pN0.05). After the last
inoculation therewas a similar result in the sera of rTGEVS-MHV/C11-VP7-
inoculated mice (37 pg/mL) for GM-CSF (pb0.05) and 22 pg/mL of IL-2
(pN0.05). In serum samples from rTGEVS-MHV/C11-inoculatedmice, both
levels of GM-CSF (47 pg/mL; pb0.05) and INF-γ (6 pg/mL; pN0.05)
increased (Fig. 8A).
At 5-day poststimulation cultures of splenocytes revealed signiﬁcant
increases of IL-10 (108 pg/mL) in rTGEVS-MHV/C11-stimulated splenocytes
from rTGEVS-MHV/C11-VP7-inoculated mice and in rTGEVS-MHV/C11
(300 pg/mL; pN0.05) and RF (63 pg/mL; pN0.05)-stimulated spleno-
cytes from rTGEVS-MHV/C11-inoculated mice. No signiﬁcant increases of
GM-CSF or IFN-γwere found (Fig. 8B).
Protection against diarrhea induced by rotavirus of pups born to dams
immunized with rTGEVS-MHV/C11-VP7
We tested whether mothers immunized with rTGEVS-MHV/C11-VP7
can transfer antibodies to their newborns and thus protect them against
diarrhea induced by rotavirus challenge. Four-day-old newborns from
female BALB/cmice intragastrically or intreperitoneally inoculatedwith
rTGEVS-MHV/C11-VP7 were challenged with an oral inoculum of 2×106
FFU of bovine rotavirus strain RF or 10 DD50 of murine rotavirus strain
EDIM. To assess infection, we evaluated diarrhea during the 4-day
period following viral challenge. A passive protection against rotavirus-
induced diarrhea was transferred to the newborn pups (Fig. 9). Sixty-
two percent of pups born to dams inoculated intraperitoneally were
protected against RF rotavirus strain diarrhea. Fisher's exact test did not
show any signiﬁcant difference in protection levels between this group
and theRF strain-challenged newborn offspring of RF strain-immunized
Fig. 5.Detectionof rTGEVS-MHV/C11 antigen inhistological sectionsof tissue samplesof rTGEVS-MHV/C1-inoculatedSTAT1−/−mice.Micewere inoculatedwith2×106 FFUof rTGEVS-MHV/C11.
Twodays later intestine (A), lungs (B), liver (C) and spleen (D) tissue sampleswere collected. Histological sections of tissueswereprepared and stainedwithMab3D.C10 raised against the
N protein. FITC-conjugated secondary antibody was then used to visualize viral protein by immunoﬂuorescence.
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of intragastrically inoculated dams were protected against diarrhea.
Signiﬁcant differences were found between the proportion of protected
pups in this group and the corresponding control group (p=0.013).
Eighteen percent of newborn offspring of intraperitoneally immunized
dams inoculated with EDIM rotavirus did not develop diarrhea.
Differences between this group and EDIM-challenged control mice
were statistically signiﬁcant (p=0.001).
Discussion
This study conﬁrms that coronavirus TGEV genomes can incorpo-
rate heterologous gene sequences and express them and supports
their potential use as vaccine vectors. An infectious cDNA clone of
TGEV has been genetically engineered to incorporate the rotavirus
VP7 gene, replacing nonessential 3a and 3b genes, and a mono-
cistronic vector expressing the VP7 protein stably in vitro for at least
ﬁve passages has been developed.
Two attenuated human oral rotavirus vaccines are currently
available worldwide. Rotarix (Glaxo-Smith-Kline), a human attenu-
ated rotavirus vaccine, and RotaTeq (Merck), a human-bovine
reassortant rotavirus vaccine, were shown to be efﬁcacious against
severe rotavirus disease in many countries (Dennehy, 2008; Parashar
and Glass, 2009) but in Malawi and South Africa the efﬁcacy was only
49.4% and 76.9%, respectively (Madhi et al., 2010). Other live,
attenuated oral vaccines such as vaccine 116E, based on rotaviruses
obtained from asymptomatically infected newborns in Delhi, India,
are also undergoing clinical trials (Bhandari et al., 2009). Improved
vaccines are still needed, particularly in developing countries, and also
for veterinarian applications.
In recent years, different heterologous genes have been cloned and
expressed in coronavirus (de Haan et al., 2005; Fischer et al., 1998;
Sola et al., 2003). This makes them attractive candidates for the
development of genetically modiﬁed live vaccines or for use in genetherapy. The identiﬁcation of nonessential genes in the viral genome
represents an important step to identify viral genes involved in
virulence and to incorporate foreign genes in coronavirus vectors, as
accessory genes may be deleted leading to attenuated viruses and
providing appropriate insertion targets for heterologous genes. In
TGEV, 3a and 3b are genes encoding viral nonstructural proteins
whose function is not essential for in vitro or in vivo virus replication
and can be deleted (Ortego et al., 2002; Sola et al., 2003). The gene
encoding GFP protein has been cloned in the position occupied by
genes 3a and 3b in the TGEV genome, achieving high expression levels
of this protein (Sola et al., 2003).
The natural host of TGEV, the pig, is a suitablemodel for studying the
immune response and the expression of heterologous recombinant
proteins, although it is expensive and difﬁcult to manage and assess.
Fortunately, coronavirus tropismcan be genetically engineered to adapt
porcine speciﬁcity of TGEV to themurinemodel, which is an affordable,
measurable and widely used animal model. Attenuation of the virus
withmodiﬁed tropismwhen it replicates in other host-cellmachinery is
yet another advantage for its use in vaccine design.
The S glycoprotein is responsible for virus binding to speciﬁc cell
receptors present on the membrane of susceptible cells, besides
inducing the fusion of viral and cellular membranes during viral entry.
This gene is a determinant of viral tropism and pathogenesis in
coronavirus (Casais et al., 2003; Navas et al., 2001; Sanchez et al.,
1999), but not the only one (Casais et al., 2003; Ortego et al., 2003). In
this study we produced TGEV virus with a chimeric S protein derived
from TGEV and MHV S proteins. In order to assemble a functional S
protein it was important to incorporate into the recombinant S gene the
two HR domains involved in S protein supercoiling (HR-1 and HR-2)
from the same viral strain (Godeke et al., 2000). In our construct HR-1
andHR-2 domains fromMHVwere used to generate a chimeric protein.
These domains have been identiﬁed in all coronavirus S proteins.
The results reported in this manuscript show that, in the case of
TGEV, species tropismwas controlled mainly at the level of viral entry
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Fig. 6. IgG antibody response elicited by immunization with rTGEVS-MHV/C11-VP7 vector.
Groups of ﬁve female BALB/c mice were immunized with three doses of 106 FFU of
rTGEVS-MHV/C11-VP7 by either the intragastric, intranasal, or intraperitoneal routes
three times at two-weekly intervals. Mice in the control group received three doses of
2×106 FFU of rTGEVS-MHV/C11 (void vector) by the intragastric route with the same
schedule. Mice were bled at the indicated points. TGEV (A) and rotavirus (B)-speciﬁc
serum IgG antibodies were determined by ELISA. *Signiﬁcantly higher than levels of the
negative control sera (pb0.05 by the Mann–Whitney test).
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Fig. 7. Serum IgA response to TGEV. Mice were immunized three times at two-weekly
intervals with 2×106 FFU/mL of rTGEVS-MHV/C11 or LR7 cells lysates (negative control).
Serum samples were collected from all mice at the indicated time points. Serum IgA to
TGEV were assayed by ELISA. Data are means±SD (six mice per group). *Signiﬁcantly
higher than levels of the preimmune sera (pb0.05 by the Rang Wilcoxon test).
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tropism replicated in murine cells, it reached titers of at least 1 log
lower than the parental virus MHV. This suggests that the replication
machinery of TGEV is slightly less efﬁcient in mouse cells, and that
speciﬁc cell factors present in porcine cells may be required for
optimum virus replication. In other reports in which S chimeric
proteins were assembled between MHV (murine tropism) and FIPV
(feline tropism) the viral titer decreased from 10 to 100 times,
providing additional support for the requirement of species-speciﬁc
cell factors for optimum coronavirus replication (Kuo et al., 2000).
BALB/c and STAT1−/− mice were inoculated to determine the in
vivo response to the infection with the recombinant rTGEVS-MHV/C11
murine virus. MHV usually causes subclinical infection, producing
signiﬁcant mortality in immunodeﬁcient mice only (Compton et al.,
1993). There are two major disease patterns of MHV based on the
tropism of the viral strain, the respiratory and the enteric pattern,which have been identiﬁed by intranasal inoculation of mice with
different MHV strains (Barthold and Smith, 1984). In the enteric
pattern (mainly produced by JHM strain), the virus infects intestinal
mucosa and spreads to the organs and bloodstream.Meanwhile, in the
respiratory pattern (represented by A-59 strain) the virus primarily
replicates in the nasal cavity and infects the olfactory bulb, thus
entering the brain through the olfactory nerve. The inhaled virus
invades the lungs,with subsequent viremia anddissemination to other
organs through the bloodstream. Our data suggest that the recombi-
nant rTGEVS-MHV/C11 virus follows a respiratory rather than an enteric
pattern. The virus infected both strains of mice evaluated in this study,
BALB/c and immunocompromised STAT1−/− mice. In addition to
having changed species tropism, a modiﬁcation in tissue tropism was
also observed. The recombinant virus replicated in the lungs, showing
a respiratory pattern similar to the parental virus MHV-A59, infecting
the sameorgans but less efﬁciently. Viral RNAwas detected in different
organs, and replication was conﬁrmed by immunoﬂuorescence assays
on tissue sections. In fact, infectious virus was recovered by cell
culture. These results were conﬁrmed by analyzing the kinetics of viral
RNA detection. Our data suggest that the recombinant virus was
attenuated inmice, particularly if its virulence is comparedwith that of
MHV, which is lethal for STAT1−/−mice (Durbin et al., 1996). These
authors showed that litters of this knockout mouse died of fulminant
hepatitis. The engineered rTGEVS-MHV/C11 vector was attenuated in
STAT1−/−mice as no deaths were recorded in this mouse strain.
The results of this study show that the engineered rTGEV vector
promoted an immune response in BALB/c mice to the vector itself and to
the rotavirus VP7 protein. The recombinant virus triggered a humoral
response in mice via systemic (serum IgG and IgA) and mucosal
(intestinal IgA) antibodies. Nevertheless, only partial protection was
achieved. This could be due to the limited stability of the heterologous
gene within the vector. The stability of heterologous genes within viral
vectors is associated to virus recombination andmutation rates. Insertion
of foreign genes in coronavirus may result in large deletions rather than
pointmutations (deHaan et al., 2005), and these deletions can be caused
by intra and inter-molecular recombination events (Lai, 1996). The
emergence of deletion variants without foreign genesmay led to viruses
withhigherﬁtness. Probably this is themaindrawback that compromises
coronaviruses efﬁcacy as vectors. Besides, recombinant proteinsmay also
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Fig. 8. Cytokine responses in BALB/c mice after immunization with rTGEVS-MHV/C11 and rTGEVS-MHV/C11-VP7. Mice were immunized intragastrically three times at two-weekly
intervals with 2×106 PFU of rTGEVS-MHV/C11 or 1×106 FFU of rTGEVS-MHV/C11-VP7, and serum was obtained 15 days after the last inoculation. Serum samples were also obtained
2 days after the ﬁrst inoculation from both mice groups (A). Two weeks after the last immunization, mice were sacriﬁced and their spleens were collected. After erythrocyte
depletion, splenocytes were cultured in 24-well plates at a concentration of 2×106 cells/mL. The cells were either stimulated with the mitogen ConA (5 μg/mL), TGEV coronavirus
(2×106 FFU), RF rotavirus (5×106 FFU) or cultured without stimulation. Cytokine levels were measured in the culture supernatants at the 5th day poststimulation (B). The levels of
cytokines were evaluated by amultiplex ﬂuorescent bead immunoassay for quantitative detection of 10mouse cytokines (FlowCytomixmouse Th1/Th2 10plex, Bender Medsystem)
and ﬂow cytometry (Beckman Coulter). Data are mean values±SD. *Signiﬁcantly higher than cytokine levels produced by preimmune sera or not stimulated splenocytes (pb0.05 by
the Mann–Whitney test or Wilcoxon test). Non S, nonstimulated.
114 J.M. Ribes et al. / Virology 410 (2011) 107–118contain toxic domains that can affect the level of heterologous gene
expression. In principle, this limitation can be overcome by identiﬁcation
of these toxic domains and their elimination by site-directed
mutagenesis.
Previous attempts to develop a rotavirus vaccine through the
expression of cloned genes encoding the outer capsid proteins VP4 or
VP7 have achieved diverse results. In most studies, trials immunizing
animals against rotavirus by VP7 protein expression have been of
limited success due to the complexity and instability of neutralization
domains of the expressed VP7 (McGonigal et al., 1992; Salas-Vidal
et al., 1990). In other studies, only antibodies to denatured VP7 were
induced, indicating that the expressed protein was immunogenic;
however, it did not elicit the formation of antibodies that neutralized
virus (Johnson et al., 1989; Salas-Vidal et al., 1990). Some authorssuggest that calcium binding is necessary to form the neutralization
domain on expressed VP7 (Dormitzer et al., 1994). Studies of VP7
expression in prokaryotic vectors (E. coli and attenuated strains of S.
typhimurium) obtained disappointing results (Arias et al., 1986;
McCrae and McCorquodale, 1987). Expression of rotavirus in vaccinia
virus vector gave good results when VP7was expressed on the plasma
membrane of infected cells, which was achieved by adding the
membrane anchor and cytoplasmatic domain from inﬂuenza virus
hemagglutinin (Andrew et al., 1990). Similar results were reported for
the same VP7 construct expressed in a recombinant type 5 adenovirus
(Both et al., 1993).
The immunization of BALB/c mice with rTGEVS-MHV/C11-VP7 vector
stimulated an anti-rotavirus antibody response. The intraperitoneal
routewasmore effective in inducing a signiﬁcant response after theﬁrst
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Fig. 9. Passive protection of newborns against rotavirus-induced diarrhea. Female mice
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VP7. Immunized females were mated with males. Four-day-old newborns were orally
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dams. The symbols * and ** indicate signiﬁcant differences with respect to the EDIM and
RF control groups (pb0.05), respectively. N.D., determined.
115J.M. Ribes et al. / Virology 410 (2011) 107–118inoculation than the intragastric or intranasal routes. This antibody
response was enhanced after the second inoculation and was
maintained after the third inoculation. Speciﬁc antibody response to
the vector itself was detected inmice inoculated by all three routes. The
virus may infect organs through mucosal surfaces at low efﬁciency,
whereas a direct route of inoculation, such as the intraperitoneal route,
probably led to an increased viral replication allowing a wider
dissemination of the vector to other tissues, and thus a stronger
immune response.
Production ofmucosal IgA antibodies against VP7was not detected
in BALB/c mice inoculated intragastrically with rTGEVS-MHV/C11-VP7.
In contrast, anti-TGEV intestinal IgA antibodies were induced after
intragastric inoculation with rTGEVS-MHV/C11, although in only two out
of six inoculated mice. The low replication of the recombinant virus in
BALB/c mice probably hampered the antibody IgA response in
mucosal areas.
Our results showed a trend towards a Th2-type immune response
elicited by rTGEVS-MHV/C11-VP7 vector, as revealed with the produc-
tion of IL-10 by stimulated splenocytes from inoculated mice. IL-10
was induced only after splenocyte stimulation with rTGEVS-MHV/C11
virus, but not with rTGEVS-MHV/C11-VP7, possibly due to a lower
priming by this recombinant. In line with our results, enhanced IL-10
production has also been reported in splenocytes of mice coinfected
with MHV and Trypanosoma cruzi, and endogenous IL-10 down-
regulates IFN-γ production (Torrecilhas et al., 1999). Furthermore, we
found an increase in GM-CSF levels in the serum and in stimulated
splenocytes of the inoculated mice. GM-CSF strongly inﬂuences the
biological functions of many different phagocytic and immune cells,
stimulating the production of granulocytes and monocytes (Rasko,
1997).
Protection against rotavirus diarrhea by passive maternal transfer
of antibodies has been previously reported for mice immunized with
live rotavirus vaccines (Ofﬁt and Clark, 1985), recombinant adenovi-
rus expressing VP7 protein (Both et al., 1993) or rotavirus VLPs (Coste
et al., 2000). We observed that maternal rotavirus-speciﬁc antibodies
partially protected suckling newborns against rotavirus-induced
diarrhea. Suckling pups born to dams inoculated with rTGEV-VP7 by
the intragastric or intraperitoneal routes were challenged orally withhomotypic (RF) or heterotypic (EDIM) rotavirus. Sixty-two percent of
pups from mothers immunized intraperitoneally were protected
against rotavirus RF diarrhea, although only 13% of pups frommothers
immunized intragastrically were also protected. However, when
challenged with the heterotypic murine EDIM strain, only 18% of
pups born to intraperitoneally immunized dams were protected
against diarrhea. These results are consistent with the differences in
VP7 antigenicity between RF (G6 serotype) and EDIM (G3 serotype)
rotavirus strains and also coincide with antibody production, because
only female mice that produced rotavirus-speciﬁc antibodies pro-
tected their pups against rotavirus-induced diarrhea. The expression
of other VP7 proteins with different antigenic speciﬁcities and the
simultaneous coexpression of different rotavirus proteins must be
addressed in order to achieve more efﬁcient protection against
rotavirus infection using TGEV-derived vectors.
In conclusion, a partial protection against rotavirus-induced
diarrhea was achieved in suckling BALB/c mice born to dams
immunized with the recombinant coronavirus expressing VP7 when
they were orally challenged with the homotypic rotavirus strain.Materials and methods
Cell cultures and viruses
Baby hamster (BHK21), porcine swine testis (ST), human colon
adenocarcinoma (Caco-2) and murine ﬁbroblast (LR7, 3T3 and MC57)
cells were grown in Dulbecco's modiﬁed Eagle's medium (DMEM).
Simian kidney (MA104) and murine BALB Cl.7 cells were culture in
MEMwithglutamine (2 mM).All cell culturemediawere supplemented
with 10% fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin
(100 μg/mL) and tylosin (100 UI/mL). All reagentswere purchased from
Gibco-Invitrogen. CMR cells are Caco-2 transfected with the MHV
receptor gene and were supplemented with geneticin G418
(500 μg/mL) (Sigma) in order to stably express the recombinant MHV
receptor glycoprotein (Rossen et al., 1997). The TGEV strain PUR46-
MAD was derived from the Purdue strain by 120 passages on ST cells
involving three cloning steps by plaque puriﬁcation (Sanchez et al.,
1990).MHV-A59was obtained fromATCC. The rotavirus strain RFwas a
gift from J. Cohen (Laboratoire de Virologie et d'Immunologie
Moleculaire, INRA, France). The EDIM strain of murine rotavirus was
kindly provided by R. Ward (Children's Hospital, Cincinnati, Ohio).
Viral stocks and standard virus titrations were performed in porcine
ST (TGEV) (Correa et al., 1988), murine LR7 (recombinant virus) and
MA104 cells (rotavirus) (L'Haridon and Scherrer, 1976). Virus titrations
were performed by plaque formation (TGEV and MHV-A59) and
immunoﬂuorescence assay (rotavirus and recombinant virus). EDIM
rotavirus was replicated by orally infecting 5- to 7-day-old BALB/c
suckling mice. The 50% diarrhea dose (DD50) was determined by oral
inoculation of pups with serial 10-fold dilutions of the viral stock.Mice
BALB/c mice were purchased from Charles River Laboratories
(Barcelona, Spain) and STAT1−/− mice were kindly provided by M.
Mueller (Ludwig Boltzmann Institute for Immunogenetic, Cytogenet-
ic, and Molecular Genetic Research, Vienna, Austria). Inoculated mice
were held in an animal storage unit (UA-I, EuroAire, Spain) under
negative pressure to prevent the environmental spread of the
recombinant viruses. All animals were housed in a conventional
animal facility at the University of Valencia and food and water were
supplied ad libitum. All experiments were carried out using a protocol
approved by the Animal Care and Ethics Committee of the University
of Valencia pursuant European Directive 86/609/CEE, amendment
2003/65/CE, and Spanish Act RD1201/2005.
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The TGEV M protein-speciﬁc monoclonal antibody (MAb) 3B.B3
has been described previously (Risco et al., 1995) and the MAb
speciﬁc for MHV S protein was a kind gift from J. Fleming (University
of Southern California). The MAb 3D.C10 speciﬁc for the TGEV N
protein was used to detect TGEV antigen in small intestine sections
(Jimenez et al., 1986). VP7 rotavirus protein was detected with an
anti-VP7 MAb provided by G. Gerna (Policlinico San Matteo, Pavia,
Italy) and with a sheep polyclonal anti-rotavirus antibody (Silenus
Laboratories, Melbourne, Australia). The anti-VP6 MAb 2F3.E7 that
recognizes the rotavirus inner capsid was developed in our laboratory
and was used in seroneutralization assays.
Construction of the pBAC-TGEVS-MHV/C11
To generate the chimerical S gene MHV-A59/TGEVC11 the restriction
site MluI (3264) was deleted in the gene S of MHV-A59. To generate the
deletion, oligonucleotide primers S-MHV-2452-VS (5′-GTTGCTAGTGCAT
TAATGC-3′) and S-MHV-3277(C)-RS (5′-GAAATTAATACGGGTGGTTT
GGC-3′), inserting a point mutation (G3264→C), were used to generate
a PCRproduct fromnucleotides (nt) 2452 to 3277of theMHV-A59gene S.
The primers S-MHV-3254(C)-VS (5′-GCCAAACCACCCGTATTAATTTC-3′),
including the point mutation (G3264→C) and S-MHV-3803-RS (5′-
AACATACCAAGGCCATTTC-3′) were used to generate a PCR product from
nt 3254 to 3803 of the MHV-A59 gene S. Both overlapping PCR products
were used as templates for PCR ampliﬁcation using the primers S-MHV-
2452-VS andMHV-S-3803-RS. The ampliﬁedDNAwasdigestedwithXhoI
and StyI and cloned into the XhoI-StyI-digested pGem4Z-SMHV-A59 to
obtain the pGem4Z-SMHV-A59-ΔMluI plasmid. To generate the plasmid
pGem4Z-S-A59-C11-PacI-MluI, the unique restriction sites PacI and MluI
were inserted into the chimerical gene S. The oligonucleotide primers S-
MHV-Hind-Pac-1-VS (5′-CGAAGCTTAATTAAGAAGGGTAAGTTGCTCAT-
TAGAAATAATGGTAAGTTACTAAACTTTGGTAACCACTTCGTTAACACAC-
CATGCTGTTCGTGTTTATTCTATTTTTG-3′), including a HindIII site
(underlined), a PacI site (boldface nucleotides), 71 nucleotides from the
5′ transcription regulatory sequence (TRS) of gene S of TGEV, and theﬁrst
27 nucleotides of the gene S of MHV-A59, and S-MHV-867-RS (5′-
GGTATAACTACTACGACAATC-3′) were used to generate a PCR product
comprising fromnt 1 to nt 867of the of theMHV-A59gene S. PCRproduct
was digested with HindIII and SpeI and cloned into the HindIII-SpeI-
digested pGem4Z-SMHV-A59-ΔMluI plasmid, generating pGem4Z-
SMHV-A59-ΔMluI-PacI. The primers S-C11-VS (5′-AAATGGCCTTGG-
TATGTGTGG), and 3′-S-C11-Mlu-Bam-RS (5′-GCGGATCCACGCGTAAGTT-
TAGTTCTTAAAGAC-3′), including a BamHI site (underlined), and a MluI
site (boldface nucleotides), were used to generate a PCR product from nt
4158 to 4347 of the TGEV-C11 gene S. PCR productwas digestedwith StyI
and BamHI and cloned into the StyI-BamHI-digested pGem4Z-SMHV-
A59-ΔMluI-PacI to obtain the pGem4Z-SMHV-A59-ΔMluI-Pac-Mlu plas-
mid. To assemble pBAC-TGEV-SMHV-C11 encoding the TGEV full-length
genome with the chimerical SMHV-C11 gene, the pGem4Z-SMHV-A59-
ΔMluI-Pac-Mlu plasmid was digested with PacI and MluI and the
chimerical gene SMHV-C11 cloned into PacI-MluI-digested pBAC-TGEV-
P-M (Ortego et al., 2003).
Construction of the pBAC-TGEVS-MHV/C11-VP7
Rotavirus VP7 gene was ampliﬁed by PCR from the cDNA clone
pcDNA-RfORF9 (generously provided by J. Cohen) using oligonucleo-
tides that inserted ﬂanking MluI and BlpI restriction sites at the 5′ end
and 3′ end of the PCR product. The oligonucleotide primers 5′-ORF9-VS
(5′GCACGCGTCATTACAGGTCCTTGTATGGACTATATAATTTACAGA-
TTTCTGCTTATAGTGATCTTGGCC-3′), including aMluI site (underlined),
and 3′-ORF 9-RS (5′-GCGCGCTAAGCTACACTCTATAGTAGAACGCCGAC-
GAAT-3′) including a BlpI site (underlined) were used to amplify VP7.
The PCR product was digested with MluI and BlpI and cloned into theMluI-BlpI-digested pACNR1180-TGEV-SPTV-RS (Ortego et al., 2003) to
obtain the pACNR1180-TGEV-SPTV-RS-Δ3ab-ORF9 plasmid, containing
the coding sequence of the rotavirus VP7 gene and the transcription
regulating sequence (TRS)of TGEV3a gene. Aspreviously described, this
TRS-3a produces efﬁcient transcription of heterologous sequences (Sola
et al., 2003). To generate pBAC-TGEV-SMHV-C11-VP7, the pACNR1180-
TGEV-SPTV-RS-Δ3ab-ORF9 plasmid was digested with MluI and BamHI
and the rotavirus VP7, and TGEV E, M, N, and seven genes cloned into
MluI-BamHI-digested pBAC-TGEV-SMHV-C11.
Immunoﬂuorescence assay
Cell monolayers grown on glass coverslips were infected at a MOI
of 1 in DMEM containing 2% FBS and DEAE-dextran (80 μg/mL). After
90 min of incubation, the extracellular virus was removed, and the
cells were further cultured in DMEM 2% FBS. After rinsing with PBS,
cells were ﬁxed with methanol/acetone or with 4% paraformaldehyde
in PBS for confocal studies. In the latter case the cells were rinsed with
PBS 0.1% Triton X-100 in order to permeabilise the cell membrane. For
dual-labeling experiments inwhich the primary antibodywas derived
from mouse or from rabbit, both antibodies were combined in PBS
with 20% FBS. Antibodies were allowed to adsorb for 90 min at room
temperature, and washed three times with PBS-2% FBS. The coverslips
were mounted on glass slides with glycerol (Light Diagnostics) and
observations made with a ﬂuorescence microscope (Nikon Eclipse
E600) or by confocal microscopy (Confocal Leica TCS SP analyzedwith
Leica Lite Software).
RNA extraction and RT-PCR
Viral RNA was extracted with Trizol-LS (Invitrogen) from infected
cell culture lysates or tissue homogenates according to the manufac-
turer's instructions. To obtain tissue homogenates the organs were
extracted and triturated using a glass tissue homogenizer and then
resuspended in PBS (10%w/v) containing 200 IU penicillin/mL, 200 μg
streptomycin, and 10 UI/mL nystatin. The tissue suspensions were
clariﬁed by centrifugation at 10,000×g for 5 min at 4 °C, and then
passed through a 0.2 μm membrane ﬁlter and eventually stored at
−80 °C.
A two-step reverse transcriptase PCR (RT-PCR) was performed with
the following procedure. cDNA was synthesized using AMV reverse
transcriptase (Promega) for 35 min at 42 °C. cDNAwasampliﬁedbyPCR
using primer pairs targeting the nucleocapsid TGEV sequence gene and
the VP7 rotavirus gene. They were primer leader 15 (5' GTGAGTG-
TAGCGTGGCTATATCTCTTC 3'; positions 15–41) and TN224
(5' CCTTCACCATGCGATAGC 3'; positions 224–241) for the N gene, and
primer leader 15 and 253RF (5' CTGCATACGCAGTATCCATTG 3';
positions 233–253) for rotavirus VP7 gene. Primers designed to amplify
a fragment of the RNA encoding mice glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) housekeeping gene (GAPDH forward 5′
TGCATCCTGCACCACCAACT 3′, positions 502–520, and reverse 5′
TGCATCCTGCACCACCAACT 3′ positions to 832–850) were used as an
internal control for RNA extraction from tissues. The PCR cycling
conditions were the following: 1 cycle of 94 °C for 1 min; 40 cycles of
94 °C for 1 min, 45 °C for 1 min, and 72 °C for 2 min, and a ﬁnal
extension step at 72 °C for 10 min.
Detection of rTGEVMHV-S virus by immunohistochemistry
Small intestine, lung, liver and spleen tissue samples were ﬁxed in
4% buffered formalin and embedded in parafﬁn (Leica ASP 300 S tissue
processor). Serial 2-μm sections (Leica RM 2155 microtome) were
mounted on polylysine-coated slides (Polysine, Menzel-Glaser). For
the immunoﬂuorescence assay, sectionswere deparafﬁnized for 1 h at
65 °C. Antigen retrieval was performed by heating at 98 °C for 40 min
in citrate buffer (10 mM sodium citrate, pH 6.0), and slides were
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anti-N of TGEV, diluted 1:20, was applied for 2 h at room temperature.
Subsequently, a FITC-labeled anti-mouse IgG secondary antibody was
used and eventually the sectionswere counterstainedwith Evans blue
dye (0.01% in PBS).
Mice immunizations
Six- to eight-week-old female BALB/c mice in groups of ﬁve mice
were inoculated with rTGEVMHV-S-VP7 propagated in DMEM with 2%
FBS containing 1×107 ﬂuorescent focus-forming units/mL (FFU/mL).
Mice were conﬁrmed by ELISA to have no serum IgG antibody to
rotavirus prior to immunization and were inoculated three times at
two-weekly intervals by three alternative routes (two groups per each
route): (i) intragastrically, by placing 200 μL of viral inoculum
containing 2×106 FFU/mouse into the lower esophagus using a
gavage needle, (ii) oro-nasally, by instilling 10 μL of viral suspension
containing 1×106 FFU directly in each nostril with a micropipette
under isoﬂurane anesthesia, and (iii) intraperitoneally, by injecting
100 μL of viral inoculum containing 1×106 FFU into the abdominal
cavity.
Sample collection and processing
Blood samples were collected at 15 days postinoculation by
mandibular bleeding and incubated for 4 h at room temperature,
centrifuged for 10 min at 3000×g, and the sera were stored at−20 °C.
Fecal samples were collected from each mouse at 20 days postinoc-
ulation and diluted to 1:10 (w/v) in PBS. The suspensions were
clariﬁed by centrifugation and supernatants stored at −80 °C.
Analyses of antibodies to rotavirus and coronavirus by ELISA
Antibody production to rotavirus and coronavirus antigens were
determined by enzyme-linked immunosorbent assay (ELISA) as
previously described (Dormitzer et al., 1994). The levels of neutralizing
antibodies against rotaviruses were also determined by a focus
reduction neutralization assay. Brieﬂy, serum samples were inactivated
for 30 min at 56 °C and serially diluted 4-fold in MEM (Gibco). All
dilutions were incubated in the presence of 50–100 peroxidase focus
forming-units of rotavirus RF strain for 1 h at 37 °C. Then, eachmix was
added in duplicate to MA104 cell culture monolayers grown in 96-well
microtiter plates (Costar) and incubated at 37 °C. At 18 h.p.i., the cells
were ﬁxed with methanol/acetone and an immunoperoxidase assay
was performed. Brieﬂy, MAb 2F3E7 against rotavirus VP6 protein was
diluted in 1:200 in PBS-BSA and allowed to reactwith themonolayer for
1 h at 37 °C. After three washes, the secondary antibody HRP-
conjugated against mouse IgG (Sigma) diluted 1:2000 in PBS-BSA was
added for 1 h at 37 °C. The plates were thenwashed ﬁve timeswith PBS
and stained with DAB (Fast DAB, Sigma). Neutralizing titers were
considered as the inverse of the sample dilution that showed 60%
reduction of peroxidase focus forming-units.
Cytokine production assay
Five mice per group of 6- to 8-week-old female BALB/c mice were
inoculated intragastrically three times with 106 FFU/mice of rTGEV-
MHV-S-VP7 or rTGEVMHV-S viruses. Mice were bled 2 days after the ﬁrst
inoculation and 15 days after the last inoculation, then sacriﬁced and
spleens were extracted. Blood samples were collected by mandibular
puncture 2 days postinoculation.
Spleen cell cultures and stimulation
Spleen single-cell suspensions were prepared by mechanical
dissociation in RPMI 1640 medium supplemented with 100 U/mLpenicillin, 100 μg/mL streptomycin, 10 mM HEPES, and 2% FBS.
Splenocytes obtained from animals of the same groups were
separately pooled. Cells were washed and spleen erythrocytes were
removed by osmotic lysis with erythrocyte lysis buffer (155 mM
NH4Cl, 10 mM KHCO3, 1 mM Na2EDTA pH 7.3). Splenocytes were
cultured in 24-well plates at a cell density of 2.5×106 cells/well.
Lymphocyte restimulation was performed by supplementing culture
medium with TGEV coronavirus (2×106 FFU), RF rotavirus (5×106
FFU) or concanavalin A (5 μg/mL). After 5 days of incubation at 37 °C
supernatants were collected for cytokine detection and quantiﬁcation.
Cytokine levels were determined using the FlowCytomix Mouse Th1/
Th2 10plex (Bender MedSystems) following the manufacturer's
instructions. Data analyses were performed using MXP Software to
generate standard curves for each cytokine and to determine sample
cytokine levels.
Mouse protection experiments
Newborn mice were obtained from rTGEVMHV-S-VP7-immunized
female BALB/c mice mated with rTGEVMHV-S-VP7-naive male BALB/c
mice. Litters of 4-day-old newborns were orally given 10μL of EDIM
murine rotavirus (10 DD50) or RF bovine rotavirus (2×106 FFU). This
inoculum of the RF rotavirus strain induces diarrhea in 90% of
challenged animals (Coste et al., 2000). The presence of diarrhea was
recorded for 5 days after inoculation. Diarrhea was deﬁned as the
production of very ﬂuid bright yellow stools following very gentle
abdominal palpation of the mouse, combined with fecal material on
the skin and around the anus.
Statistical analysis
In those experiments performed to analyze antibody and cytokine
production the nonparametric test was applied to determine the
presence or absence of signiﬁcant differences between groups.
Different proportions were compared using the two-tailed Fisher's
exact test. In all cases p-values below 0.05 were considered
statistically signiﬁcant. The Mann–Whitney test was used to compare
independent samples and the Wilcoxon test was applied for
dependent sample comparisons. All the analyses were performed by
using the SPSS software vs. 14.0 (LEAD Technologies, Inc.).
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